Should patients undergoing chemotherapy and radiotherapy be prescribed antioxidants?

Integrative Cancer Therapies

Volumn 5, Issue 1, 2006, Pages 63-82

  Moss, Ralph W ^a  

^a Cancer Communications Inc   (United States)

Author keywords

carotene; Antioxidants; Chemotherapy; Coenzyme Q10; Free radicals; Immunosuppression; Malnutrition; Melatonin; Neurotoxicity; Ototoxicity; Radiotherapy; Vitamin C; Vitamin E

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; AMIFOSTINE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; CARBOPLATIN; CHLORAMBUCIL; CISPLATIN; CLODRONIC ACID; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; GLUTATHIONE; MELATONIN; MESNA; METHOTREXATE; NICOTINIC ACID; OXALIPLATIN; PACLITAXEL; PENTOXIFYLLINE; PROANTHOCYANIDIN DERIVATIVE; PROMETHAZINE; RAZOXANE; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RETINOL; SELENIUM; THIOCTIC ACID; UBIDECARENONE; UNINDEXED DRUG; ZINC;

ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOIMMUNE DISEASE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE NECROSIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER THERAPY; CARDIOMYOPATHY; CARDIOTOXICITY; CHEMOPROPHYLAXIS; CHEMOTHERAPY INDUCED EMESIS; CLINICAL PROTOCOL; CLINICAL TRIAL; DIET SUPPLEMENTATION; DRUG EFFICACY; DRUG POTENTIATION; HEAD AND NECK CANCER; HEARING LOSS; HEART INJURY; HELICOBACTER PYLORI; HEMORRHAGIC CYSTITIS; HUMAN; LEUKOPENIA; LUNG CANCER; LUNG SMALL CELL CANCER; MALNUTRITION; MEDICAL PRACTICE; MUCOSA INFLAMMATION; NAUSEA; NERVE INJURY; NEUROTOXICITY; NONHUMAN; NUTRITION; OTOTOXICITY; OVARY CANCER; PATIENT CARE; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PROCTITIS; RADIATION INJURY; RISK ASSESSMENT; STOMACH CANCER; TINNITUS; XEROSTOMIA;

ANTIOXIDANTS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEOPLASMS; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; SURVIVAL ANALYSIS; THERAPIES, INVESTIGATIONAL; TREATMENT OUTCOME;

EID: 33144480157     PISSN: 15347354     EISSN: None     Source Type: Journal    
DOI: 10.1177/1534735405285882     Document Type: Article

References (116)

1. D'Andrea GM. Use of antioxidants during chemotherapy and radiotherapy should be avoided. CA Cancer J Clin. 2005 ; 55: 319-321.
2. Parker-Pope T. Cancer and vitamins: patients urged to avoid supplements during treatment. Wall Street Journal. September 20, 2005: D1.
3. Cohen MH. Complementary and Alternative Medicine: Legal Boundaries and Regulatory Perspectives. Baltimore, Md: Johns Hopkins University Press ; 1997.
4. Moss RW. Antioxidants Against Cancer. Brooklyn, NY: Equinox Press ; 2000.
5. Prasad KN. Multiple dietary antioxidants enhance the efficacy of standard and experimental cancer therapies and decrease their toxicity. Integr Cancer Ther. 2004 ; 3: 310-322.
6. Conklin KA. Dietary antioxidants during cancer chemotherapy: impact on chemotherapeutic effectiveness and development of side effects. Nutr Cancer. 2000 ; 37: 1-18.
7. Conklin K. Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness. Integr Cancer Ther. 2004 ; 3: 294-300.
8. Jiang Q, Wong J, Fyrst H, Saba JD, Ames BN. Gammatocopherol or combinations of vitamin E forms induce cell death in human prostate cancer cells by interrupting sphingolipid synthesis. Proc Natl Acad Sci U S A. 2004 ; 101: 17825-17830.
9. Ferrari CK. Functional foods, herbs and nutraceuticals: towards biochemical mechanisms of healthy aging. Biogerontology. 2004 ; 5: 275-289.
10. Drisko JA, Chapman J, Hunter VJ. The use of antioxidant therapies during chemotherapy. Gynecol Oncol. 2003 ; 88: 434-439.
11. Chen Q, Espy MG, Krishna MC, et al. Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci U S A. 2005 ; 102: 13604-13609.
12. Paiva SAR, Russell RM. Beta-carotene and other carotenoids as antioxidants. J Am Coll Nutr. 1999 ; 18: 426-433.
13. Young AJ, Lowe GM. Antioxidant and prooxidant properties of carotenoids. Arch Biochem Biophys. 2001 ; 385: 20-27.
14. Bairati I, Meyer F, Gelinas M, et al. Randomized trial of anti-oxidant vitamins to prevent acute adverse effects of radiation therapy in head and neck cancer patients. J Clin Oncol. 2005 ; 23: 5805-5813.
15. Bairati I, Meyer F, Gelinas M, et al. A randomized trial of anti-oxidant vitamins to prevent second primary cancers in head and neck cancer patients. J Natl Cancer Inst. 2005 ; 97: 481-488.
16. Camphausen K, Citrin D, Krishna MC, Mitchell JB. Implications for tumor control during protection of normal tissues with antioxidants. J Clin Oncol. 2005 ; 23: 5455-5457.
17. Block K. Antioxidants in the news. Integr Cancer Ther. 2005 ; 4: 271-273.
18. Creagan ET, Moertel CG, O'Fallon JR, et al. Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer: a controlled trial. N Engl J Med. 1979 ; 301: 687-690.
19. Moertel CG, Fleming TR, Creagan ET, Rubin J, O'Connell MJ, Ames MM. High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy: a randomized double-blind comparison. N Engl J Med. 1985 ; 312: 137-141.
20. Padayatty SJ, Sun H, Wang Y, et al. Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med. 2004 ; 140: 533-537.
21. Memorial Sloan-Kettering Cancer Center. Cancer tumors shown to consume large amounts of vitamin C [press release]. September 15, 2000. Available at: www.mskcc.com.
22. Chen Q, Espey MG, Krishna MC, et al. Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci U S A. 2005 ; 102: 13604-13609.
23. Cheraskin E, Ringsdorf WM Jr, Hutchins K, Setyaadmadja AT, Wideman GL. Effect of diet upon radiation response in cervical carcinoma of the uterus: a preliminary report. Acta Cytol. 1968 ; 12: 433-438.
24. Newbold HL. Vitamin C Against Cancer. New York, NY: Stein & Day ; 1979.
25. Gonzalez MJ, Miranda-Massari JR, Mora EM, et al. Orthomolecular oncology review: ascorbic acid and cancer 25 years later. Integr Cancer Ther. 2005 ; 4: 32-44.
26. Jaakkola K, Lahteenmaki P, Laakso J, Harju E, Tykka H, Mahlberg K. Treatment with antioxidant and other nutrients in combination with chemotherapy and irradiation in patients with small-cell lung cancer. Anticancer Res. 1992 ; 12: 599-606.
27. Lesperance ML, Olivotto IA, Forde N, et al. Mega-dose vitamins and minerals in the treatment of non-metastatic breast cancer: an historical cohort study. Breast Cancer Res Treat. 2002 ; 76: 137-143.
28. Pajak TF. Methodology of clinical trials. In: Perez CA, Brady LW, eds. Principles and Practice of Radiation Oncology. 3rd ed. Philadelphia, Pa: Lippincott-Raven ; 1997: 231-242.
29. Rudoler SB, Winter K, Curran WJ Jr. Methodology of clinical trials. In: Perez CA, Brady LW, Halperin EC, Schmidt-Ullrich RK, eds. Principles and Practice of Radiation Oncology. 4th ed. Philadelphia, Pa: Lippincott Williams & Wilkins ; 2004.
30. Alam N, Shepherd FA, Winton T, et al. Compliance with postoperative adjuvant chemotherapy in non-small cell lung cancer: an analysis of National Cancer Institute of Canada and intergroup trial JBR.10 and a review of the literature. Lung Cancer. 2005 ; 47: 385-394.
31. Hoffer A. Comments on "Mega-Dose Vitamins and Minerals in the Treatment of Nonmetastatic Breast Cancer: An Historical Cohort Study." Integr Cancer Ther. 2003 ; 2: 155-157.
32. Fisher B, Anderson S, Redmond C, Wolmark N, Wickerham DL, Cronin WM. Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med. 1995 ; 333: 1456-1461.
33. Clark RM, Whelan T, Levine M, et al. Randomized clinical trial of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer: an update. J Natl Cancer Inst. 1996 ; 88: 1659-1664.
34. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer. 1973 ; 32: 302-314.
35. Alexander J, Dainiak N, Berger HJ, et al. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. N Engl J Med. 1979 ; 300: 278-283.
36. Magne N, Largillier R, Marcy PY, Magne J, Namer M. Cardiac toxicity assessment in locally advanced breast cancer treated neoadjuvantly with doxorubicin/paclitaxel regimen. Support Care Cancer. 2005 ; 13: 819-825.
37. Conklin K. Coenzyme q10 for prevention of anthracycline-induced cardiotoxicity. Integr Cancer Ther. 2005 ; 4: 110-130.
38. Bertazzoli C, Sala L, Ballerini L, Watanabe T, Folkers K. Effect of adriamycin on the activity of the succinate dehydrogenasecoenzyme Q10 reductase of the rabbit myocardium. Res Commun Chem Pathol Pharmacol. 1976 ; 15: 797-800.
39. Cortes EP, Gupta M, Chou C, Amin VC, Folkers K. Adriamycin cardiotoxicity: early detection by systolic time interval and possible prevention by coenzyme Q10. Cancer Treat Rep. 1978 ; 62: 887-891.
40. Lafluer P. Vitamin E supplements may speed up development of cancer, study says [communiqué]. Québec, Canada: Universit Laval ; April 5, 2005. Available at: http://www.scom.ulaval.ca/Communiques.de.presse/2005/ avril/vitaminecancer.html.
41. Brash DE, Havre PA. New careers for antioxidants. Proc Natl Acad Sci U S A. 2002 ; 99: 13969-13971.
42. Shin DM, Khuri FR, Murphy B, et al. Combined interferon-alfa, 13-cis-retinoic acid, and alpha-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial. J Clin Oncol. 2001 ; 19: 3010-3017.
43. Seixas-Silva JA Jr, Richards T, Khuri FR, et al. Phase 2 bioadjuvant study of interferon alfa-2a, isotretinoin, and vitamin E in locally advanced squamous cell carcinoma of the head and neck: long-term follow-up. Arch Otolaryngol Head Neck Surg. 2005 ; 131: 304-307.
44. Fossa SD. Long-term sequelae after cancer therapy: survivorship after treatment for testicular cancer. Acta Oncol. 2004 ; 43: 134-141.
45. Pace A, Savarese A, Picardo M, et al. Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy. J Clin Oncol. 2003 ; 21: 927-931.
46. Ferreira PR, Fleck JF, Diehl A, et al. Protective effect of alpha-tocopherol in head and neck cancer radiation-induced mucositis: a double-blind randomized trial. Head Neck. 2004 ; 26: 313-321.
47. Argyriou AA, Chroni E, Koutras A, et al. Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial. Neurology. 2005 ; 64: 26-31.
48. Delanian S, Porcher R, Balla-Mekias S, Lefaix JL. Randomized, placebo-controlled trial of combined pentoxifylline and tocopherol for regression of superficial radiation-induced fibrosis. J Clin Oncol. 2003 ; 21: 2545-2550.
49. Delanian S, Depondt J, Lefaix JL. Major healing of refractory mandible osteoradionecrosis after treatment combining pentoxifylline and tocopherol: a phase II trial. Head Neck. 2005 ; 27: 114-123.
50. Pathak AK, Bhutani M, Guleria R, et al. Chemotherapy alone vs. chemotherapy plus high dose multiple antioxidants in patients with advanced non small cell lung cancer. J Am Coll Nutr. 2005 ; 24: 16-21.
51. Kennedy M, Brunuinga K, Mutlu EA, Losurdo J, Choudhary S, Keshavarian A. Successful and sustained treatment of chronic radiation proctitis with antioxidant vitamins E and C. Am J Gastroenterol. 2001 ; 96: 1080-1084.
52. Mahmoud F, Sarhill N, Mazurczak MA. The therapeutic application of melatonin in supportive care and palliative medicine. Am J Hosp Palliat Care. 2005 ; 22: 295-309.
53. Jang MH, Jung SB, Lee MH, et al. Melatonin attenuates amyloid beta 25-35-induced apoptosis in mouse microglial BV2 cells. Neurosci Lett. 2005 ; 380: 26-31.
54. Lissoni P, Chilelli M, Villa S, Cerizza L, Tancini G. Five years survival in metastatic non-small cell lung cancer patients treated with chemotherapy alone or chemotherapy and melatonin: a randomized trial. J Pineal Res. 2003 ; 35: 12-15.
55. Cerea G, Vaghi M, Ardizzoia A, et al. Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations. Anticancer Res. 2003 ; 23: 1951-1954.
56. Lissoni P, Malugani F, Bukovec R, et al. Reduction of cisplatin-induced anemia by the pineal indole 5-methoxytryptamine in metastatic lung cancer patients. Neuro Endocrinol Lett. 2003 ; 24: 83-85.
57. Lissoni P, Bucovec R, Bonfanti A, et al. Thrombopoietic properties of 5-methoxytryptamine plus melatonin versus melatonin alone in the treatment of cancer-related thrombocytopenia. J Pineal Res. 2001 ; 30: 123-126.
58. Moss RW. Cancer and complementary and alternative medicine in Italy: personal observations and historical considerations. Integr Cancer Ther. 2004 ; 3: 173-188.
59. Rybak LP, Husain K, Morris C, Whitworth C, Somani S. Effect of protective agents against cisplatin ototoxicity. Am J Otol. 2000 ; 21: 513-520.
60. Miyajima A, Nakashima J, Tachibana M, Nakamura K, Hayakawa M, Murai M. N-acetylcysteine modifies cisdichlorodiammineplatinum-induced effects in bladder cancer cells. Jpn J Cancer Res. 1999 ; 90: 565-570.
61. Locatelli MC, D'Antona A, Labianca R, et al. A phase II study of combination chemotherapy in advanced ovarian carcinoma with cisplatin and cyclophosphamide plus reduced glutathione as potential protective agent against cisplatin toxicity. Tumori. 1993 ; 79: 37-39.
62. Di Re F, Bohm S, Oriana S, Spatti GB, Zunino F. Efficacy and safety of high-dose cisplatin and cyclophosphamide with glutathione protection in the treatment of bulky advanced epithelial ovarian cancer. Cancer Chemother Pharmacol. 1990 ; 25: 355-360.
63. Di Re F, Bohm S, Oriana S, et al. High-dose cisplatin and cyclophosphamide with glutathione in the treatment of advanced ovarian cancer. Ann Oncol. 1993 ; 4: 55-61.
64. Bohm S, Oriana S, Spatti G, et al. Dose intensification of platinum compounds with glutathione protection as induction chemotherapy for advanced ovarian carcinoma. Oncology. 1999 ; 57: 115-120.
65. Smyth JF, Bowman A, Perren T, et al. Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: results of a double-blind, randomised trial. Ann Oncol. 1997 ; 8: 569-573.
66. Cascinu S, Cordella L, Del Ferro E, Fronzoni M, Catalano G. Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial. JClinOncol. 1995 ; 13: 26-32.
67. Cascinu S, Catalano V, Cordella L, et al. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2002 ; 20: 3478-3483.
68. Schmidinger M, Budinsky AC, Wenzel C, et al. Glutathione in the prevention of cisplatin induced toxicities: a prospectively randomized pilot trial in patients with head and neck cancer and non small cell lung cancer. Wien Klin Wochenschr. 2000 ; 112: 617-623.
69. National Cancer Institute. Overview of nutrition in cancer care. June 17, 2005. Available at: http://www.cancer.gov/cancerinfo/pdq/supportivecare/ nutrition
70. Weijl NI, Hopman GD, Wipkink-Bakker A, et al. Cisplatin combination chemotherapy induces a fall in plasma antioxidants of cancer patients. Ann Oncol. 1998 ; 9: 1331-1337.
71. Evans WK, Nixon DW, Daly JM, et al. A randomized study of oral nutritional support versus ad lib nutritional intake during chemotherapy for advanced colorectal and non-small-cell lung cancer. J Clin Oncol. 1987 ; 5: 113-124.
72. Ladner C, Ehninger G, Gey KF, Clemens MR. Effect of etoposide (VP16-213) on lipid peroxidation and antioxidant status in a high-dose radiochemotherapy regimen. Cancer Chemother Pharmacol. 1989 ; 25: 210-212.
73. Clemens MR, Ladner C, Ehninger G, et al. Plasma vitamin E and beta-carotene concentrations during radiochemotherapy preceding bone marrow transplantation. Am J Clin Nutr. 1990 ; 51: 216-219.
74. Donaldson SS, Lenon RA. Alterations of nutritional status: impact of chemotherapy and radiation therapy. Cancer. 1979 ; 43: 2036-2052.
75. Clemens MR, Waladkhani AR, Bublitz K, Ehninger G, Gey KF. Supplementation with antioxidants prior to bone marrow transplantation. Wien Klin Wochenschr. 1997 ; 109: 771-776.
76. Colasanto JM, Prasad P, Nash MA, Decker RH, Wilson LD. Nutritional support of patients undergoing radiation therapy for head and neck cancer. Oncology (Williston Park). 2005 ; 19: 371-379.
77. Hektoen L, Corper HJ. The effect of mustard gas (dichloroethlsulphid[e]) on antibody formation. J Infect Dis. 1920: 28: 279-285.
78. Pechura CM, Rall DP, eds. Veterans at Risk: The Health Effects of Mustard Gas and Lewisite. Washington, DC: Institute of Medicine of the National Academies ; 1993. Available at: http://www.nap.edu/catalog/2058.html.
79. Barratt TM, Soothill JF. Controlled trial of cyclophosphamide in steroid-sensitive relapsing nephrotic syndrome of childhood. Lancet. 1970 ; 2: 479-482.
80. Pras E, Neumann R, Zandman-Goddard G, et al. Intraocular inflammation in autoimmune diseases. Semin Arthritis Rheum. 2004 ; 34: 602-609.
81. Burt RK, Traynor AE, Pope R, et al. Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation. Blood. 1998 ; 92: 3505-3514.
82. Shah MA, Kortmansky J, Motwani M, et al. A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol. Clin Cancer Res. 2005 ; 11: 3836-3845.
83. Lissoni P, Paolorossi F, Ardizzoia A, et al. A randomized study of chemotherapy with cisplatin plus etoposide versus chemoendocrine therapy with cisplatin, etoposide and the pineal hormone melatonin as a first-line treatment of advanced non-small cell lung cancer patients in a poor clinical state. J Pineal Res. 1997 ; 23: 15-19.
84. Yu D, Duan Y, Bao Y, Wei C, An L. Isoflavonoids from Astragalus mongholicus protect PC12 cells from toxicity induced by L-glutamate. J Ethnopharmacol. 2005 ; 98: 89-94.
85. Taixiang W, Munro AJ, Guanjian L. Chinese medical herbs for chemotherapy side effects in colorectal cancer patients. Cochrane Database Syst Rev. 2005: CD004540.
86. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet. 2003 ; 362: 1255-1260.
87. Jacobs P. Loophole boosts biotech profits. Mercury News. December 26, 2004. Available at: http://www.mercurynews.com/mld/mercurynews/.
88. Angell M. The Truth About the Drug Companies: How They Deceive Us and What to Do About It. New York, NY: Random House ; 2004.
89. Moss RW. The Cancer Industry. Rev ed. Lemont, Pa: Equinox Press ; 1996.
90. Kennedy DD, Ladas EJ, Rheingold SR, Blumberg J, Kelly KM. Antioxidant status decreases in children with acute lymphoblastic leukemia during the first six months of chemotherapy treatment. Pediatr Blood Cancer. 2005 ; 44: 378-385.
91. Kennedy DD, Santella RM, Wang Q, et al. 8-oxo-dG elevated in children during leukemia treatment. Integr Cancer Ther. 2004 ; 3: 301-309.
92. Kennedy DD, Tucker KL, Ladas ED, Rheingold SR, Blumberg J, Kelly KM. Low antioxidant vitamin intakes are associated with increases in adverse effects of chemotherapy in children with acute lymphoblastic leukemia. Am J Clin Nutr. 2004 ; 79: 1029-1036.
93. Salganik RI. The benefits and hazards of antioxidants: controlling apoptosis and other protective mechanisms in cancer patients and the human population. JAmCollNutr. 2001 ; 20: 464S - 472S.
94. Salganik R. Study: avoiding vitamins A, E might improve cancer therapy [press release]. December 14, 1999. Available at: http://www.sciencedaily.com/ releases/1999/12/991214072746.htm.
95. Food and Drug Administration, Center for Drug Evaluation and Research. FDA oncology tools approval summary for mesna for prevention of ifosfamide-induced hemorrhagic cystitis, 1988. Available at: http://www.accessdata.fda.gov/scripts/cder/onctools/summary.cfm?ID=103.
96. Mashiach E, Sela S, Weinstein T, Cohen HI, Shasha SM, Kristal B. Mesna: a novel renoprotective antioxidant in ischaemic acute renal failure. Nephrol Dial Transplant. 2001 ; 16: 542-551.
97. Yildirim I, Korkmaz A, Oter S, Ozcan A, Oztas E. Contribution of antioxidants to preventive effect of mesna in cyclophosphamide-induced hemorrhagic cystitis in rats. Cancer Chemother Pharmacol. 2004 ; 54: 469-473.
98. Ozcan A, Korkmaz A, Oter S, Coskun O. Contribution of flavonoid antioxidants to the preventive effect of mesna in cyclophosphamide-induced cystitis in rats. Arch Toxicol. 2005 ; 79: 461-465.
99. Food and Drug Administration. Zinecard (dexrazoxane for injection). NDA 20-212/S-008. Available at: http://www.fda.gov/medwatch/safety/2005/MAY_PI/ Zinecard_PI.pdf.
100. Food and Drug Administration, Center for Drug Evaluation and Research. FDA oncology tools approval summary for dexrazoxane for reducing the incidence and severity of cardiomyopathy, October 31, 2002. Available at: http://www.accessdata.fda.gov/scripts/cder/onctools/summary.cfm?ID=256.
101. Hensley ML, Schuchter, LM, Lindley, C, et al. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol. 1999 ; 17: 3333-3355.
102. Marzatico F, Porta C, Moroni M, et al. In vitro antioxidant properties of amifostine (WR-2721, Ethyol). Cancer Chemother Pharmacol. 2000 ; 45: 172-176.
103. Kemp G, Rose P, Lurain J, et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. JClinOncol. 1996 ; 14: 2101-2112.
104. Food and Drug Administration, Oncology Division Advisory Committee. Fulfillment of the accelerated approval requirements for the non-small cell lung cancer indication: ethyol (Amifostine) reduces the cumulative renal toxicity associated with repeated administration of cisplatin in patients with advanced non-small cell lung cancer. Available at: http://www.fda.gov/ohrms/dockets/ac/ 03/briefing/3936B1_05_MedImmune-Eythol.htm.
105. Schiller JH. High-dose cisplatin and vinblastine plus amifostine for metastatic non-small cell lung cancer. Semin Oncol. 1996 ; 23: 78-82.
106. Brizel DM, Wasserman TH, Henke M, et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol. 2000 ; 18: 3339-3345.
107. Lipshultz SE, Rifai N, Dalton VM, et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med. 2004 ; 351: 145-153.
108. Omenn GS, Goodman GE, Thornquist MD, et al. Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. J Natl Cancer Inst. 1996 ; 88: 1550-1559.
109. Food and Drug Administration. Gefitinib (marketed as Iressa) information. 2005. Available at: http://www.fda.gov/cder/drug/infopage/gefitinib/default. htm.
110. Mosman Communications, Inc. Industry news: AstraZeneca posts US$21B sales. Medical Observer. May 15, 2005. Available at: http://www.medobserver.com/mar2005/indnews.html.
111. Tung N, Berkowitz R, Matulonis U, et al. Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer. Gynecol Oncol. 2000 ; 77: 271-277.
112. Lissoni P, Barni S, Brivio F, Rossini F, Fumagalli L, Tancini G. Treatment of cancer-related thrombocytopenia by low-dose subcutaneous interleukin-2 plus the pineal hormone melatonin: a biological phase II study. J Biol Regul Homeost Agents. 1995 ; 9: 52-54.
113. Lissoni P, Tancini G, Paolorossi F, et al. Chemoneuroendocrine therapy of metastatic breast cancer with persistent thrombocytopenia with weekly low-dose epirubicin plus melatonin: a phase II study. J Pineal Res. 1999 ; 26: 169-173.
114. Susser M. Causes of peptic ulcer: a selective epidemiological review. J Chronic Dis. 1967 ; 20: 435-456.
115. Altman LK. Nobel came after years of battling the system. New York Times. October 11, 1005.
116. Ioannidis JPA. Why most research findings are false. PLOS Medicine. 2005 ; 2: e124. Available at: http://medicine.plosjournals.org/perlserv/?request=get- document&doi=10.1371/journal.pmed.0020124.